--- title: "CMC & Quality Readiness: Avoiding the Gaps That Delay First-in-Human Trials" description: "Discover the most common CMC and quality gaps that delay First-in-Human trials and learn how to align manufacturing, regulatory, and clinical readiness." url: https://qbdgroup.com/en/blog/cmc-quality-readiness-first-in-human-trials type: "Blog post" language: en published: 2026-06-24 author: "Angeles Escartí-Nebot" category: "Regulatory Affairs" publisher: "QbD Group" citation: "QbD Group, \"CMC & Quality Readiness: Avoiding the Gaps That Delay First-in-Human Trials\", https://qbdgroup.com/en/blog/cmc-quality-readiness-first-in-human-trials" --- # CMC & Quality Readiness: Avoiding the Gaps That Delay First-in-Human Trials > Discover the most common CMC and quality gaps that delay First-in-Human trials and learn how to align manufacturing, regulatory, and clinical readiness. For early-stage biotech companies, reaching First-in-Human (FIH) is often described as a regulatory milestone. In practice, it is equally a CMC milestone. A promising non-clinical package and a well-designed clinical strategy are essential, but neither can move forward without confidence in the product being administered to patients. Manufacturing readiness is sometimes treated as a later-stage topic when, in reality, it plays a critical role well before pivotal development. For First-in-Human studies, regulators are not expecting commercial-scale maturity; they are expecting sufficient control, appropriate product understanding, and reliable supply to support safe clinical use. **In this blog post** - What CMC readiness really means at the First-in-Human stage - Why CMC gaps continue to delay CTA and IND submissions - The most common quality and manufacturing questions raised by regulators - How to align CMC, regulatory, and clinical timelines - What sponsors should prioritise to avoid avoidable delays ## What CMC Readiness Really Means at First-in-Human A common misconception is that CMC readiness for First-in-Human requires the same level of maturity expected later in development. In reality, regulators apply a phase-appropriate lens. The question is not whether the package is complete in the commercial sense, but whether the investigational product can be manufactured under sufficient control, adequately characterised, and reliably tied to a safe and interpretable trial. From a regulatory perspective, CMC readiness at First-in-Human typically means five things. ### Regulators Typically Expect Five Things - The drug substance and drug product are sufficiently characterised, and the clinical batch is demonstrably comparable to the material used in the non-clinical safety studies. - The manufacturing process is described, controlled, and consistent for the batches actually used, supported by phase-appropriate cGMP and a quality system that fits the stage of development. - Specifications and analytical methods are scientifically justified and qualified for their purpose, underpinned by a coherent impurity and contamination control strategy, including adventitious-agent control where biological materials are involved. - Container-closure suitability, potency, and stability data adequately bracket the proposed clinical use. - Every remaining gap relative to commercial expectations is bridged by an explicit, risk-based justification rather than left unstated. These expectations are fundamental because CMC at First-in-Human is gating, not interpretive. > **CMC at First-in-Human is gating, not interpretive. If the product is not sufficiently controlled, or not comparable to the material used in non-clinical studies, the trial does not start.** In the US, an IND may be placed on clinical hold under 21 CFR 312.42. In the EU, the competent authority may refuse to authorise the trial under Regulation (EU) No 536/2014. CMC quality at First-in-Human is therefore not simply about how cleanly future data will read. It is the precondition for entering the clinic at all. ## Why CMC Gaps Create Delays So Often For biotech companies preparing a CTA or IND, CMC gaps rarely emerge because of a single technical problem. More often, they appear when development workstreams move at different speeds. Clinical timelines advance, non-clinical packages progress, and regulatory planning moves forward, while manufacturing activities remain partly open or supporting documentation falls behind. The result is often a last-minute scramble to address questions that could have been anticipated much earlier. ### The Same Questions Keep Appearing Regulators consistently raise questions in a handful of recurring areas: - Manufacturing process definition - Specifications and control strategy - Analytical methods and product characterisation - Stability and clinical supply - Manufacturing changes and comparability For early-stage biotech companies, these are rarely isolated technical issues. More often, they are symptoms of broader misalignment between CMC, regulatory, and clinical workstreams. Building the right level of quality oversight early, while keeping development activities synchronised, helps teams avoid unnecessary delays and maintain momentum toward First-in-Human milestones. ## The Planning Challenge: Keeping CMC Aligned With Clinical Timelines For early-stage biotech companies, the hardest challenge is often not any individual technical requirement. It is coordination. CMC development needs to move in parallel with regulatory and clinical planning, not behind it. That means synchronising manufacturing activities with CTA and IND timelines, ensuring supply readiness early enough to avoid operational pressure, and maintaining visibility of future development phases while focusing on the immediate milestone. A practical CMC plan at this stage should answer several important questions: - When will clinical material need to be available? - Which GMP activities must be completed before submission? - Is available stability data aligned with the proposed trial timeline? - Are analytical methods sufficient to support release and interpretation? - Could process changes impact comparability with earlier batches? - Which CMC decisions made today could affect later development phases? That level of planning does not require overbuilding. It requires prioritisation, visibility, and alignment across teams. When manufacturing readiness, regulatory expectations, and clinical timelines remain aligned, First-in-Human preparation tends to move efficiently. When they drift apart, delays become significantly more likely. ## A Strategic Milestone, Not Just a Technical One For emerging biotech companies, First-in-Human is a defining inflection point, clinically, operationally, and commercially. CMC readiness is a critical part of that foundation. Not because every element must be fully finalised, but because confidence in the clinical product underpins everything that follows: - Patient safety - CTA and IND progress - Operational execution - The credibility of generated clinical data The earlier CMC planning becomes part of the broader development conversation, alongside regulatory strategy and clinical planning, the easier it becomes to reduce avoidable rework and move into the clinic with confidence. For teams preparing the transition to First-in-Human, that alignment is often the difference between a programme that progresses as planned and one that loses valuable time at a critical stage. ## Strengthening Your CMC Readiness for First-in-Human Preparing a CTA or IND requires more than a strong scientific package. It requires a CMC strategy that supports regulatory expectations, clinical timelines, and reliable product supply. QbD Group supports biotech companies with: - CMC development strategy - Quality oversight and phase-appropriate GMP implementation - CTA and IND preparation - Analytical and comparability strategies - Clinical supply and stability planning ## References - European Medicines Agency (EMA). Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev.1). - European Medicines Agency (EMA). Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (EMA/CHMP/QWP/545525/2017 Rev.2). - European Commission. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. - European Medicines Agency (EMA). ICH Guideline Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. --- Source: https://qbdgroup.com/en/blog/cmc-quality-readiness-first-in-human-trials — © QbD Group. Quote freely with attribution and a link back.